Reinventing ESMO after the COVID-19 pandemic: moving towards a sustainable academic society
Name:
PIIS2059702924002990.pdf
Size:
1.178Mb
Format:
PDF
Description:
Found with Open Access Button
Authors
Crona, J.Lee, Rebecca
Sobczuk, P.
Wysoki, O.
Devnani, B.
Prasongsook, N.
Scheffler, M.
Jalving, M.
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, ManchesterIssue Date
2024
Metadata
Show full item recordCitation
Crona J, Lee R, Sobczuk P, Wysoki O, Devnani B, Prasongsook N, et al. Reinventing ESMO after the COVID-19 pandemic: moving towards a sustainable academic society. ESMO open. 2024 May;9(5):102531. PubMed PMID: 38796283. Pubmed Central PMCID: PMC11145755 Fabre, AstraZeneca, Chromition. PS has received travel grants from MSD, Roche, Novartis and Pierre Fabre, honoraria for lectures from Swixx BioPharma, Sandoz and BMS and advisory board honoraria from Sandoz. BD was an invited speaker for the Sabah Rectal Cancer Society, Malaysia. NP has received speaker/advisory board fees from Roche (Thailand), AstraZeneca, Novartis, Bristol Myers Squibb, Pfizer, Amgen. MS has received funding from Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Novartis, Pfizer, Roche, Sanofi-Aventis, Siemens Healthineers and Takeda, institutional research support from Amgen, BMS, Dracen Pharmaceuticals, Janssen, Novartis, Siemens Healthineers and Takeda, travel support from AstraZeneca, Boehringer Ingelheim, Janssen, Pfizer. MJ has received advisory board fees from BMS, Pierre Fabre, Merck, all paid to institution. All other authors have declared no conflicts of interest. Epub 2024/05/26. eng.Journal
ESMO OpenDOI
10.1016/j.esmoop.2024.102531PubMed ID
38796283Additional Links
https://dx.doi.org/10.1016/j.esmoop.2024.102531Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.esmoop.2024.102531